75 related articles for article (PubMed ID: 15231874)
1. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.
Ezzat S; Zheng L; Asa SL
Mol Endocrinol; 2004 Oct; 18(10):2543-52. PubMed ID: 15231874
[TBL] [Abstract][Full Text] [Related]
2. Signaling mechanisms of neurite outgrowth induced by the cell adhesion molecules NCAM and N-cadherin.
Hansen SM; Berezin V; Bock E
Cell Mol Life Sci; 2008 Nov; 65(23):3809-21. PubMed ID: 18791849
[TBL] [Abstract][Full Text] [Related]
3. NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.
Lehembre F; Yilmaz M; Wicki A; Schomber T; Strittmatter K; Ziegler D; Kren A; Went P; Derksen PW; Berns A; Jonkers J; Christofori G
EMBO J; 2008 Oct; 27(19):2603-15. PubMed ID: 18772882
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.
Gabler L; Jaunecker CN; Katz S; van Schoonhoven S; Englinger B; Pirker C; Mohr T; Vician P; Stojanovic M; Woitzuck V; Laemmerer A; Kirchhofer D; Mayr L; LaFranca M; Erhart F; Grissenberger S; Wenninger-Weinzierl A; Sturtzel C; Kiesel B; Lang A; Marian B; Grasl-Kraupp B; Distel M; Schüler J; Gojo J; Grusch M; Spiegl-Kreinecker S; Donoghue DJ; Lötsch D; Berger W
Acta Neuropathol Commun; 2022 Apr; 10(1):65. PubMed ID: 35484633
[TBL] [Abstract][Full Text] [Related]
5. N-cadherin and β1 integrin coordinately regulate growth plate cartilage architecture.
Greer SE; Haller SJ; Lee D; Dudley AT
Mol Biol Cell; 2024 Apr; 35(4):ar49. PubMed ID: 38294852
[TBL] [Abstract][Full Text] [Related]
6. Neural cell adhesion molecule (N-CAM) is required for cell type segregation and normal ultrastructure in pancreatic islets.
Esni F; Täljedal IB; Perl AK; Cremer H; Christofori G; Semb H
J Cell Biol; 1999 Jan; 144(2):325-37. PubMed ID: 9922458
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast Growth Factor Receptor 4 Deficiency Mediates Airway Inflammation in the Adult Healthy Lung?
Easter M; Garth J; Harris ES; Shei RJ; Helton ES; Wei Y; Denson R; Zaharias R; Rowe SM; Geraghty P; Faul C; Barnes JW; Krick S
Front Med (Lausanne); 2020; 7():317. PubMed ID: 32793609
[TBL] [Abstract][Full Text] [Related]
8. Receptor FGFRL1 acts as a tumor suppressor in nude mice when overexpressed in HEK 293 Tet-On cells.
Zhuang L; Steinberg F; Trueb B
Oncol Lett; 2016 Dec; 12(6):4524-4530. PubMed ID: 28101211
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues.
Saksis R; Rogoza O; Niedra H; Megnis K; Mandrika I; Balcere I; Steina L; Stukens J; Breiksa A; Nazarovs J; Sokolovska J; Konrade I; Peculis R; Rovite V
Cancer Cell Int; 2023 Feb; 23(1):25. PubMed ID: 36774501
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions.
Lu L; Wan X; Xu Y; Chen J; Shu K; Lei T
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454025
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling.
Ferguson HR; Smith MP; Francavilla C
Cells; 2021 May; 10(5):. PubMed ID: 34068954
[TBL] [Abstract][Full Text] [Related]
13. Long-read transcriptome sequencing reveals abundant promoter diversity in distinct molecular subtypes of gastric cancer.
Huang KK; Huang J; Wu JKL; Lee M; Tay ST; Kumar V; Ramnarayanan K; Padmanabhan N; Xu C; Tan ALK; Chan C; Kappei D; Göke J; Tan P
Genome Biol; 2021 Jan; 22(1):44. PubMed ID: 33482911
[TBL] [Abstract][Full Text] [Related]
14. Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?
Asa SL; Mete O; Ezzat S
Endocr Pathol; 2021 Mar; 32(1):3-16. PubMed ID: 33433883
[TBL] [Abstract][Full Text] [Related]
15. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract][Full Text] [Related]
16. Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review.
Serioli S; Doglietto F; Fiorindi A; Biroli A; Mattavelli D; Buffoli B; Ferrari M; Cornali C; Rodella L; Maroldi R; Gasparotti R; Nicolai P; Fontanella MM; Poliani PL
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817110
[TBL] [Abstract][Full Text] [Related]
17. The role of
Zlatkutė E; Liutkevičienė R; Vilkevičiūtė A; Glebauskienė B; Kriaučiūnienė L; Jakštienė S; Žaliūnienė D
Acta Med Litu; 2017; 24(4):177-190. PubMed ID: 29487481
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of regrowth in nonfunctioning pituitary tumors.
Raverot G; Vasiljevic A; Jouanneau E
Pituitary; 2018 Apr; 21(2):176-182. PubMed ID: 29288467
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Pathology of Cushing Disease: Are We Nearly There?
Grossman AB
J Endocr Soc; 2017 Feb; 1(2):144-148. PubMed ID: 29264473
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome Analysis Showed a Differential Signature between Invasive and Non-invasive Corticotrophinomas.
de Araújo LJ; Lerario AM; de Castro M; Martins CS; Bronstein MD; Machado MC; Trarbach EB; Villares Fragoso MC
Front Endocrinol (Lausanne); 2017; 8():55. PubMed ID: 28382019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
